BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15291447)

  • 1. [New therapeutic approachs in melanoma].
    Mortier L; Marchetti P; Gordower L; Charbonnier-Hatzfeld AS; Toungouz M; Velu T
    Rev Med Brux; 2004 Jun; 25(3):153-9. PubMed ID: 15291447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell vaccination as a treatment modality for melanoma.
    Eubel J; Enk AH
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New aspects of immunotherapy of malignant melanoma].
    Enk A
    Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for melanoma.
    Komenaka I; Hoerig H; Kaufman HL
    Clin Dermatol; 2004; 22(3):251-65. PubMed ID: 15262312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
    Campoli M; Ferrone S
    Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches].
    Enk AH; Becker JC; Schuler G
    J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination: role in metastatic melanoma.
    Pilla L; Valenti R; Marrari A; Patuzzo R; Santinami M; Parmiani G; Rivoltini L
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1305-18. PubMed ID: 16925496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
    Gordon LK; Ribas A; Nusinowitz S; Butterfield LH; Glaspy JA; Economou JS; Straatsma BR
    Control Clin Trials; 2004 Aug; 25(4):400-7. PubMed ID: 15296814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in cellular immunotherapy for malignant melanoma].
    López M; Escobar A; Alfaro J; Fodor M; Larrondo M; Ferrada C; Salazar-Onfray F
    Rev Med Chil; 2004 Sep; 132(9):1115-26. PubMed ID: 15543770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vaccinal cell therapy in melanoma].
    Quillien V; Lesimple T; Toujas L
    Bull Cancer; 2003; 90(8-9):722-33. PubMed ID: 14609762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possibilities of immunotherapy and gene therapy for malignant melanoma.
    Crowley NJ; Seigler HF
    Semin Surg Oncol; 1993; 9(3):273-8. PubMed ID: 8516616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations.
    Tuettenberg A; Schmitt E; Knop J; Jonuleit H
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):190-6. PubMed ID: 17338793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy.
    Gajewski TF; Louahed J; Brichard VG
    Cancer J; 2010; 16(4):399-403. PubMed ID: 20693853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma vaccines: achievements and perspectives.
    Brichard VG; Gérard C
    Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.
    Pilon-Thomas S; Verhaegen M; Kuhn L; Riker A; Mulé JJ
    Cancer Immunol Immunother; 2006 Oct; 55(10):1238-46. PubMed ID: 16315029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.